



Mastery of Obesity Care Course

Credit for this course may not exceed 12.5 credits when both the live and enduring material activity format credits are combined.

On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of **11 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **11 MOC** points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACCME Activity ID 203331129

Important Dates for On-Demand Course (Enduring Material)

Date of Release: March 23, 2026

Date of Termination: December 31, 2028

Learning Objectives

1. Differentiate obesity from other chronic diseases and outline its relapsing and progressive nature to improve long-term management strategies.
2. Evaluate the indications, efficacy, and safety profiles of combination therapies (pharmacologic, endoscopic, and surgical) for obesity management.
3. Develop personalized treatment plans by integrating advanced pathophysiology with obesity-related complications, such as MASLD, cardiovascular disease, and endocrine disorders.

4. Implement strategies to mitigate implicit and explicit bias in clinical practice and improve patient-centered obesity care.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity - including faculty, planners, reviewers or others - are required to disclose all financial relationships with ineligible entities¹ (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity. The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all financial relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate financial relationships. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed.

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

Panelists:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that "The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased."

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

Speaker Disclosures:

Burridge, Karli, PA-C, MMS, FOMA	<ul style="list-style-type: none"> • Advisor relationship with Boehringer Ingelheim and Novo Nordisk (Pharmaceuticals). • Consultant relationship with Currax (Pharmaceuticals). • Speaker relationship with Abbott (Medical Food), and Eli Lilly and Vivus (Pharmaceuticals).
George, Thomas, DNP, FNP-C, NASM-CPT, FOMA	<ul style="list-style-type: none"> • Consultant relationship with Epitomee Medical (Medical Device). • Guest speaker, one time industry sponsored obesity symposium relationship with Currax (Pharmaceuticals).
Golden, Angela, DNP, FNP-C, FAANP, FOMA	<ul style="list-style-type: none"> • Advisor relationship with Boehringer Ingelheim, Currax, Eli Lilly, and Epitomee (Pharmaceuticals), and Weight Watchers (Medical Food). • Consultant relationship with Novo Nordisk (Pharmaceuticals). • Speaker relationship with Acella (Pharmaceuticals).
Horn, Deborah, DO, MPH	<ul style="list-style-type: none"> • Consultant relationship with Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Zealand (Pharmaceuticals). • Researcher relationship with Eli Lilly and Novo Nordisk (Pharmaceuticals). • Speaker relationship with Novo Nordisk (Pharmaceuticals).
Kaplan, Lee, MD, PhD, FTOS	<ul style="list-style-type: none"> • Consultant relationship with Altimune, Amgen, AstraZeneca, Boehringer Ingelheim (Pharmaceuticals), Cytoki, Eli Lilly, Kallyope, Neurogastrx, Novo Nordisk, and Pfizer (Pharmaceuticals), and Johnson & Johnson, Oxford Medical Products, and Perspectum (Medical Device).
McConnell, Jeremy, MD, MFOMA	<ul style="list-style-type: none"> • Advisor relationship with Axsome and Eli Lilly (Pharmaceuticals), Fisher and Paykel, Nyxoah, and Zoll-Respicardia (Medical Device). • Consultant relationship with Inspire Medical Systems, Inc (Medical Device). • Speaker relationship with Avadel, Harmony Biosciences, Idorsia, and Novo Nordisk (Pharmaceuticals).
Ritten, Angela, DNP, APRN, FNP-BC	<ul style="list-style-type: none"> • Speaker relationship with Currax and Eli Lilly (Pharmaceuticals).
Simons-Linares, Roberto, MD	<ul style="list-style-type: none"> • Consultant relationship with 3D matrix, Boston Scientific, Medtronic, and Steris (Medical Device).
Tchang, Beverly, MD, DABOM	<ul style="list-style-type: none"> • Advisor relationship with Amgen, Boehringer-Ingelheim, Eli Lilly, Metsera, Novo Nordisk, Roche, Roman Health Ventures, Skye Bioscience, and Tern (Pharmaceuticals). • Stock Options relationship with Roman Health Ventures (Pharmaceuticals).

Speakers With No Relevant Financial Relationships:

Agarwal, Monica, MD, MEHP, FACE, DABOM

Bartfield, Jessica, MD, DABOM

Rao, Aditi, MD

Planner Disclosures:

Agarwal, Monica, MD, MEHP, FACE, DABOM	No Relevant Financial Relationships
Golden, Angela, DNP, FNP-C, FAANP, FOMA, FTOS	<ul style="list-style-type: none">• Advisor relationship with Boehringer Ingelheim, Currax, Eli Lilly, and Epitee (Pharmaceuticals), and Weight Watchers (Medical Food).• Consultant relationship with Novo Nordisk (Pharmaceuticals).• Speaker relationship with Acella (Pharmaceuticals).

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

1. Apovian cm, et al. *J clin endocrinol metab.* 2015;100(2):342-362.
2. Bays HE, et al. 2020. <https://obesitymedicine.Org/obesity-algorithm/> accessed February 12, 2020.
3. Garvey WT, et al. *Endocr pract.* 2016;22(suppl 3):1-203.
4. Wharton S, et al. *Cmaj.* 2020;192(31):e875-e891.
5. Melson, E., Miras, A. D., & Papamargaritis, D. (2023). Future therapies for obesity. *Clinical medicine (London, England)*, 23(4), 337–346. <https://doi.org/10.7861/clinmed.2023-0144>
6. Michael W Schwartz, Randy J Seeley, Lori M Zeltser, Adam Drewnowski, Eric Ravussin, Leanne M Redman, Rudolph L Leibel, Obesity Pathogenesis: An Endocrine Society Scientific Statement, *Endocrine Reviews*, Volume 38, Issue 4, 1 August 2017, Pages 267–296, <https://doi.org/10.1210/er.2017-00111>.
7. Bernard, M., Löbner, M., Lordick, F., Mehnert-Theuerkauf, A., Riedel-Heller, S. G., & Luck-Sikorski, C. (2022). Cancer prevention in females with and without obesity: Does perceived and internalised weight bias determine cancer prevention behaviour?. *BMC women's health*, 22(1), 511. <https://doi.org/10.1186/s12905-022-02085-2>

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated March 19, 2026.